{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu W"],"funding":["Tianjin Municipal Science and Technology Plan Program","the Distinguished Young Scholars of Tianjin","CAMS Innovation Fund for Medical Sciences","National Nature Science Foundation of China","the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences"],"pagination":["e008857"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11029269"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(4)"],"pubmed_abstract":["Background
Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL.Methods
Transplant-eligible patients with LBCL who were refractory to first-line immunochemotherapy or experiencing R/R status after salva"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma."],"pmcid":["PMC11029269"],"funding_grant_id":["22JCJQJC00070","82101933","2022-I2M-1-022","2020-I2M-C&T-B-085","2021-RC310-011","22ZYCGSY00830","2021-I2M-1-041","2022-I2M-C&T-B-089","2022-RC320-01"],"pubmed_authors":["Zou H","Liu H","Deng S","Chen L","Yi S","Ma Y","Wang H","Zheng W","Zou D","Wang J","Wang K","Xiong W","Liu W","Shi Y","Qiu L","Lv L","Peng G","Huang W","Sui W","Lv R","Wang Y","Wei J","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.","description":"Background
Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL.Methods
Transplant-eligible patients with LBCL who were refractory to first-line immunochemotherapy or experiencing R/R status after salva","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-08T06:02:10.947Z","creation":"2026-06-08T03:14:14.113Z"},"accession":"S-EPMC11029269","cross_references":{"pubmed":["38631712"],"doi":["10.1136/jitc-2024-008857"]}}